Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q1 FY2021 Earnings Presentation
19 slides from Viyash Scientific's earnings presentation, Jul 30, 2020
Slide 1: Earnings Presentation Q1 FY21
Earnings Presentation Q1 FY21 July 30, 2020
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Operational excellence despite challenging times
Operational excellence despite challenging times Revenues EBITDA margin PAT Cash from operations ₹3,103 16.8% ₹209 ₹409 Million Million Million 11.6% 290bps 82.6% 4.8x YoY YoY YoY YoY 3
Slide 4: Q1 FY21 Performance Review
Sequent & EQl Life S Q1 FY21 Performance Review ee
Slide 5: Challenging environment brings out best in SeQuent
Challenging environment brings out best in SeQuent All values in ₹ Mn Q1 FY2021 YOY “We are pleased to kick start the year with a strong Q1 FY21 performance despite the challenging external environment 3,103 Revenues 11.6% driven by the global pandemic. Europe, Turkey and LATAM contributed to the gr
Slide 6: Covid-19: Unprecedented crisis brings out the best in SeQuent Team
Covid-19 Unprecedented crisis brings out the best in SeQuent Team • Collaborative efforts to maintain eco-system and manage stakeholders with larger interest in mind • Complete support to vendors & employees, timely payments to all including banks • More than doubled medical insurance coverage for e
Slide 7: Covid-19: Overcoming operational challenges responsibly
Covid-19 Overcoming operational challenges responsibly Operating challenges Counter measures and • Intermittent lockdowns Strategic actions • Manpower availability • Longer shifts, attendance incentives, • Material supply constraints safety measures, enhanced term & medical insurance, free medical c
Slide 8: Steady performance across businesses
Steady performance across businesses All values in ₹ Mn Revenue YoY% Key Highlights Q1 FY21 Q1 FY20 YoY% Distribution (Constant currency) • Global sales grew 10.1% on constant currency basis, Formulations 2,001 1,874 6.8% 8.5% 11.6% on reported basis • API drives growth with increase of 13.4% on Eur
Slide 9: Q1 FY21 Business Review
Sequent & EQl Life S Q1 FY21 Business Review ee
Slide 10: APIs
APIs Scaling the 27 3 75% 2.5x capability curve Commercial APIs Manufacturing Sales to regulated Asset turnover facilities markets ratio Revenues in ₹ Mn Highlights YoY% Continue to expand margins through emphasis on high value products and focus on Q1 FY21 Q1 FY20 (cc) regulated markets 1,102 907 1
Slide 11: Formulations
Formulations Value creation 1,000+ 5 65% 80+ FDFs Manufacturing Sales to regulated Countries with facilities markets marketing presence Revenues in ₹ Mn Highlights YoY% EU grew 13.6% cc during the year, ahead of industry Q1 FY21 Q1 FY20 (cc) Growth driven by Benelux region and nutrition business fro
Slide 12: R&D Diverse Initiatives
R&D Diverse Initiatives Formulations 35+ 4 38% 10 Products Under R&D Centres Injectables New filings in Development US in next 3 years API 14+ 1 19 10 Molecules in R&D Centre US Filings CEP Filings pipeline 12 Alivira R&D facility
Slide 13: Carlyle transaction update
Carlyle transaction update •As announced on May 8, 2020, CA Harbor Investments (The Carlyle Group entity) entered in Binding Agreement to acquire majority stake in SeQuent Scientific Limited •Proposed transaction also triggered mandatory open offer by CA Harbor Investments and CAP V Mauritius Limite
Slide 14: Financials
Sequent & ALIVIRA Financials
Slide 15: Delivering consistently over 3+ years
Delivering consistently over 3+ years All values in ₹ Mn Revenue 3,103 3,164 2,780 2,842 2,705 2,819 3,006 2,352 2,517 2,249 2,328 1,942 1,975 Q1 Q2 Q3 Q4 EBITDA 16.8% 15.3% 17.0% 13.9% 13.3% 14.3% 12.7% 13.1% 10.6% 13.2% 521 10.0% 484 511 7.6% 385 9.6% 402 320 378 355 308 147 250 190 226 Q1 Q2 Q3 Q
Slide 16: Consolidated Financials
Consolidated Financials All values in ₹ Mn Q1 FY21 Q4 FY20 Q1 FY20 FY20 PARTICULARS Unaudited Audited Unaudited Audited Revenue from Operations 3,103 3,006 2,780 11,792 Material Consumption (1,594) (1,494) (1,431) (6,050) Gross Margin 1,508 1,512 1,349 5,742 % 48.6% 50.3% 48.5% 48.7% Operating Expen
Slide 17: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn Particulars Jun-20 Mar-20 ROCE* Net debt to EBITDA Shareholders' funds 8,070 7,428 17.8% 3.75 14.9% Minority Interest 478 447 11.7% 2.81 7.8% 1.90 Net Debt 1,903 2,155 1.23 2.9% 0.91 Investments 1,723 1,313 Tangible Assets 3,522 3,560 FY17 FY18 FY19 FY20 1Q
Slide 18: Thank You
Thank You SeQuent Scientific Limited CIN: L99999MH1985PLC036685, Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22,Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra Tel No: 491 22 4111 4777 | Website: www.sequent.in | E-mail id: info@sequent.in
Slide 19: For details, feel free to contact
For details, feel free to contact: Tushar Mistry Diwakar Pingle Abhishek Singhal Chief Financial Officer Christensen Investor Relations Investor Relations Consultant +91 22 4111 4717 +91 22 4215 0210 abhishek.s@sequent.in tushar.m@sequent.in dpingle@christensenir.com Registered Office: 301/A, ‘Dosti